Novartis’ Serelaxin Poised For Standard FDA Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the fact that Novartis’ serelaxin has been granted breakthrough therapy designation from FDA, the heart failure candidate will receive a standard 12-month review, management said during a second quarter sales and earnings call.
You may also be interested in...
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.
What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers
Companies receiving breakthrough designations seem just as unclear as investors about the value of the program.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.